Dendreon Company Profile (NASDAQ:DNDN)

About Dendreon

Dendreon logoDendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DNDN
  • CUSIP: 24823Q10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.32
  • P/E Growth: N/A
  • Market Cap: $N/A
Additional Links:
Companies Related to Dendreon:

Analyst Ratings

Consensus Ratings for Dendreon (NASDAQ:DNDN) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Dendreon (NASDAQ:DNDN)
DateFirmActionRatingPrice TargetDetails
11/12/2014Roth CapitalUpgradeSell -> Neutral$0.15View Rating Details
11/3/2014Credit Suisse Group AGInitiated CoverageNeutral$1.50 -> $0.98View Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Dendreon (NASDAQ:DNDN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2014Q3($0.10)($0.14)$78.72 million$73.10 millionViewN/AView Earnings Details
8/20/2014($0.18)($0.18)ViewN/AView Earnings Details
8/11/2014($0.25)($0.10)$73.37 million$82.16 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.24)$69.19 million$68.70 millionViewListenView Earnings Details
3/3/2014Q413($0.37)($0.17)$73.59 million$74.80 millionViewListenView Earnings Details
11/12/2013Q313($0.42)($0.44)$76.60 million$68.00 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.42)($0.45)$75.61 million$73.30 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.47)($0.48)$80.15 million$67.60 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.56)($0.26)$82.88 million$85.49 millionViewN/AView Earnings Details
11/2/2012Q312($0.75)($0.33)$80.68 million$78.00 millionViewN/AView Earnings Details
5/2/2011($0.70)($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Dendreon (NASDAQ:DNDN)
Current Year EPS Consensus Estimate: $-0.730 EPS
Next Year EPS Consensus Estimate: $-0.400 EPS


Dividend History for Dendreon (NASDAQ:DNDN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Dendreon (NASDAQ:DNDN)
No insider trades for this company have been tracked by


Latest Headlines for Dendreon (NASDAQ:DNDN)
DateHeadline logoHow Did Johnson & Johnson's Pharmaceutical Segment Do in 3Q16 ... - Market Realist (NASDAQ:DNDN) - October 21 at 7:22 AM logoHow Did Johnson & Johnson’s Pharmaceutical Segment Do in 3Q16? (NASDAQ:DNDN) - October 20 at 10:04 PM
News IconAdvantagene closes a $14.2M I/O raise through NCS (NASDAQ:DNDN) - September 12 at 4:26 PM logoConsultant: 'There may be no profitable biotechs in Seattle,' and that's OK (NASDAQ:DNDN) - September 7 at 4:47 PM
News IconJuno Facing Class Action Lawsuit - PharmaLive (press release) (subscription) (NASDAQ:DNDN) - August 17 at 10:00 PM logoHow Did JNJ's Pharmaceutical Segment Fare in 2Q16? - Market Realist (NASDAQ:DNDN) - July 22 at 4:34 PM logoHow Were Johnson & Johnson's 2Q16 Earnings Trending? - Market Realist (NASDAQ:DNDN) - July 21 at 10:07 PM logoHow Did JNJ’s Pharmaceutical Segment Fare in 2Q16? (NASDAQ:DNDN) - July 21 at 4:47 PM
News IconStocks Leading The Fight Against Cancer (NASDAQ:DNDN) - June 23 at 3:34 PM logoJohnson & Johnson's 1Q16 Earnings: Consumer Segment - Market Realist (NASDAQ:DNDN) - April 27 at 12:11 AM logoA Segment-by-Segment Breakdown of JNJ's 1Q16 Earnings - Market Realist (NASDAQ:DNDN) - April 26 at 5:35 AM logoJohnson & Johnson's 1Q15 Earnings: Changes in Growth Rate - Market Realist (NASDAQ:DNDN) - April 22 at 11:48 PM logoJohnson & Johnson’s 1Q16: Other Pharmaceuticals Franchises (NASDAQ:DNDN) - April 22 at 6:42 PM
News Iconאימונותרפיה: לנצח את הסרטן ולהרוויח כסף תוך כדי, אך לא בקלות - Bizportal (NASDAQ:DNDN) - March 31 at 9:49 AM logoFDA shuts down CTI Bio's pacritinib clinical trials; shares down 46% premarket - Seeking Alpha (NASDAQ:DNDN) - February 10 at 4:40 PM logoAre MannKind's Lenders Calling The Shots? - Seeking Alpha (NASDAQ:DNDN) - January 19 at 4:03 PM logoMy Favorite Under $5 Biotech Could Soar 150% or More (NASDAQ:DNDN) - May 6 at 8:08 AM logoThe First Rule of Short Selling Is: Don’t Talk About Short Selling (NASDAQ:DNDN) - March 12 at 11:39 PM logoDendreon’s Enhanced $445 Million Sale to Valeant Approved (NASDAQ:DNDN) - February 20 at 2:06 PM logoValeant to buy bankrupt vaccine maker Dendreon (NASDAQ:DNDN) - February 10 at 5:51 PM logoDendreon’s Price Jumps 35% Before Bankruptcy Auction Even Starts (NASDAQ:DNDN) - February 5 at 1:19 PM logoValeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) (NASDAQ:DNDN) - February 5 at 10:35 AM logoDendreon's Asset Rummage Sale Completes the Circle of Life (NASDAQ:DNDN) - January 30 at 6:01 AM logoValeant to buy Dendreon's prostate cancer vaccine Provenge (NASDAQ:DNDN) - January 29 at 11:01 PM logoValeant to buy worldwide rights to Dendreon's Provenge (NASDAQ:DNDN) - January 29 at 9:29 PM logoValeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) (NASDAQ:DNDN) - January 29 at 9:01 PM logoDendreon heads to auction without initial bidder (NASDAQ:DNDN) - December 29 at 4:40 PM logoClarification: Dendreon-Chapter 11 Filing story (NASDAQ:DNDN) - November 11 at 1:43 PM logoDendreon's Dead Enders Still Blaming Everyone But Themselves (NASDAQ:DNDN) - November 10 at 2:11 PM logoDendreon files for Ch. 11 bankruptcy protection (NASDAQ:DNDN) - November 10 at 1:31 PM logoUPDATE 2-Dendreon files for bankruptcy as cancer vaccine disappoints (NASDAQ:DNDN) - November 10 at 12:42 PM logoThe Shame and Lessons of a Dendreon Bankruptcy (NASDAQ:DNDN) - November 10 at 8:15 AM logoDendreon files for Ch 11 bankruptcy reorganization (NASDAQ:DNDN) - November 10 at 6:54 AM logoDendreon files for Chapter 11 bankruptcy (NASDAQ:DNDN) - November 10 at 2:22 AM logoIs an Impending Implosion of Dendreon Avoidable? (NASDAQ:DNDN) - August 12 at 12:54 PM logoApple And Others Should Issue Debt Now (NASDAQ:DNDN) - January 27 at 12:18 AM


Dendreon (NASDAQ:DNDN) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by Staff